the US Food and Drug Administration (FDA) approved the world’s first respiratory syncytial virus (RSV) vaccine. The shot, named Arexvy, is approved for adults aged 60 years and older and was developed by GlaxoSmithKline (GSK). GSK says the RSV vaccine will be available for older adults before this year’s RSV season, which usually starts before the winter months. Arexvy is administered through a single intramuscular injection.
Register for our free featured webinar here: A High-Throughput Droplet-Based Microfluidics Platform for Novel Enzyme Discovery and Engineering - xtalks.com/web...
Read more on this story here: Arexvy Becomes World’s First RSV Vaccine - xtalks.com/are...
Receive weekly news and webinar updates right in your inbox: xtalks.com/reg...
Listen live and interact with featured speakers on our upcoming Life Science webinars: bit.ly/2YRzAV0
Негізгі бет Arexvy Becomes World’s First RSV Vaccine
No video
Пікірлер